News
Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...
That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new ...
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...
Novo Nordisk said it would sell its popular weight-loss drug Wegovy on several telehealth platforms, including Hims.
Explore Hims & Hers' impressive Q1 2025 growth with 111% revenue increase, strategic partnerships, and innovative healthcare solutions.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Nader ...
Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback